Switch theme
Sign up to access all valuation multiples
Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.
2012
n/a
LTM Revenue $198M
LTM EBITDA $25.2M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vazyme Biotech has a last 12-month revenue of $198M and a last 12-month EBITDA of $25.2M.
In the most recent fiscal year, Vazyme Biotech achieved revenue of $190M and an EBITDA of $16.7M.
Vazyme Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vazyme Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $177M | $190M | XXX | XXX | XXX |
| Gross Profit | $339M | $126M | XXX | XXX | XXX |
| Gross Margin | 191% | 66% | XXX | XXX | XXX |
| EBITDA | $10.6M | $16.7M | XXX | XXX | XXX |
| EBITDA Margin | 6% | 9% | XXX | XXX | XXX |
| Net Profit | $81.9M | -$9.8M | XXX | XXX | XXX |
| Net Margin | 46% | -5% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Vazyme Biotech's stock price is CNY 24 (or $3).
Vazyme Biotech has current market cap of CNY 9.6B (or $1.3B), and EV of CNY 7.7B (or $1.1B).
See Vazyme Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.3B | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Vazyme Biotech has market cap of $1.3B and EV of $1.1B.
Vazyme Biotech's trades at 5.4x LTM EV/Revenue multiple, and 42.2x LTM EBITDA.
Analysts estimate Vazyme Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vazyme Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 5.6x | XXX | XXX | XXX |
| EV/EBITDA | 63.6x | XXX | XXX | XXX |
| P/E | -532.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -91.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVazyme Biotech's NTM/LTM revenue growth is 17%
Vazyme Biotech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Vazyme Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vazyme Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vazyme Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 58% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 26% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 74% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| NetraMark | XXX | XXX | XXX | XXX | XXX | XXX |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Absci | XXX | XXX | XXX | XXX | XXX | XXX |
| Bullfrog AI | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vazyme Biotech acquired XXX companies to date.
Last acquisition by Vazyme Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Vazyme Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vazyme Biotech founded? | Vazyme Biotech was founded in 2012. |
| Where is Vazyme Biotech headquartered? | Vazyme Biotech is headquartered in China. |
| Is Vazyme Biotech publicy listed? | Yes, Vazyme Biotech is a public company listed on SHG. |
| What is the stock symbol of Vazyme Biotech? | Vazyme Biotech trades under 688105 ticker. |
| When did Vazyme Biotech go public? | Vazyme Biotech went public in 2021. |
| Who are competitors of Vazyme Biotech? | Similar companies to Vazyme Biotech include e.g. Benevolent AI, NetraMark, SyntekaBio, Absci. |
| What is the current market cap of Vazyme Biotech? | Vazyme Biotech's current market cap is $1.3B |
| What is the current revenue of Vazyme Biotech? | Vazyme Biotech's last 12-month revenue is $198M. |
| What is the current EBITDA of Vazyme Biotech? | Vazyme Biotech's last 12-month EBITDA is $25.2M. |
| What is the current EV/Revenue multiple of Vazyme Biotech? | Current revenue multiple of Vazyme Biotech is 5.4x. |
| What is the current EV/EBITDA multiple of Vazyme Biotech? | Current EBITDA multiple of Vazyme Biotech is 42.2x. |
| What is the current revenue growth of Vazyme Biotech? | Vazyme Biotech revenue growth between 2023 and 2024 was 7%. |
| Is Vazyme Biotech profitable? | Yes, Vazyme Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
